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Obesity is a well-known risk factor for insulin resis-
tance, which in turn increases the risk of developing
type 2 diabetes [1]; however, the pathological mecha-
nism that links obesity and insulin resistance is not
fully understood. Recent studies suggested that adi-
pocytokines, products of adipocytes, play a role in this
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Obesity is a well known risk factor for insulin resistance and type 2 diabetes. Recently discovered
adipocyte-derived proteins (leptin and adiponectin) might contribute to the pathologic mechanism
linking obesity and insulin resistance. A total of 190 non-diabetic women were recruited from the
Obesity Clinic of Kaohsiung Municipal Hsiao-Kang Hospital, Taiwan, between February 2003
and February 2004. All participants completed a simple questionnaire. Blood pressure and body
mass index were measured; blood samples for fasting glucose, total cholesterol, high-density
lipoprotein cholesterol, triglyceride, leptin, adiponectin, and fasting insulin level were collected
after an overnight fast. Two-hour glucose level after a 75-g glucose tolerance test was deter-
mined. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as the
index of insulin resistance. Multivariate linear regression analyses were used to analyze the rela-
tionship between adipocytokines and insulin resistance after adjusting for possible confounding
factors. Leptin and adiponectin were found to be independently associated with HOMA-IR and
fasting insulin concentration, but in divergent directions, after adjusting for potential confound-
ing factors. Adiponectin, but not leptin, was associated with impaired glucose tolerance after
adjusting for potential confounding factors. The results suggest that leptin and adiponectin may
be involved in the pathophysiologic link between obesity and insulin resistance independently.
Low levels of adiponectin may increase the risks of developing impaired glucose metabolism and
type 2 diabetes.
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association. Leptin and adiponectin, two of the most
abundant adipocyte products, are thought to link
obesity, insulin resistance, and related disorders [2,3].
Leptin, an obese gene product, is a 16-kDa protein
and is predominantly expressed in adipose tissue [4].
Leptin regulates body weight by modulating appetite
and energy expenditure by acting on the hypothala-
mus and inhibiting the release of neuropeptide Y in
mice and humans [5]. Rising levels of leptin will cause
a signal to be sent to the brain, which then attempts to
protect the subject from obesity by decreasing appetite
and increasing energy expenditure. Nevertheless, most
obese humans have elevated concentrations of leptin
[6], suggesting that these people develop leptin resis-
tance. Meanwhile, studies have also shown that insulin
resistance is particularly prevalent in obese humans
and have reported an independent association between
insulin resistance and elevated plasma leptin levels
[7,8]. The coinciding plasma leptin levels, plasma
insulin levels and body fat suggest that leptin might
be involved in the link between obesity and β-cell
hypersecretion.
Adiponectin is a relatively abundant plasma pro-
tein of approximately 30 kDa in size specifically
secreted from adipose tissue [9]. Although the ex-
pression of adiponectin mRNA occurs exclusively in
adipose tissue, interestingly, the adiponectin concen-
tration is decreased in obese subjects [10]. Previous
reports have demonstrated that diabetic subjects have
lower levels of plasma adiponectin than non-diabetic
subjects, independent of body mass index (BMI) [11],
indicating an association between lower adiponectin
levels and type 2 diabetes.
Although it appears that leptin and adiponectin
may contribute to the development of insulin resistance
and type 2 diabetes in obese subjects, the association
between adiponectin and insulin resistance and type
2 diabetes may be modulated by leptin, or vice versa.
Insulin resistance is an important risk factor for type
2 diabetes. Therefore, we examined the associations
between leptin and adiponectin with insulin resis-
tance in non-diabetic women.
METHODS AND SUBJECTS
Study population
A total of 190 women were recruited from the Obesity
Clinic at Kaohsiung Municipal Hsiao-Kang Hospital,
Taiwan, between February 2005 and February 2006.
Eligible subjects were those who did not have diabetes
or were not taking medications that affect glucose,
blood pressure, or lipid metabolism. Subjects whose
body weight increased or decreased by more than
5 kg in 6 months before entering the study were also
excluded. All participants completed a simple ques-
tionnaire on their medication history and lifestyle
characteristics, including cigarette smoking accord-
ing to the categories “never”, “former” (quit smoking
at least 1 year ago) and “current smoker” (smoke more
than one cigarette/day for at least 1 year) and exercise
according to the categories “not regular” (less than
150 minutes per week at less than a moderate inten-
sity of exercise) and “regular exerciser” (at least 150
minutes per week at a moderate or greater intensity
of exercise). Written informed consent was obtained
from all study subjects, and the study was approved
by the Human Experiment and Ethics Committee of
Kaohsiung Municipal Hsiao-Kang Hospital.
Anthropometry and blood pressure
assessment
Height and body weight were measured without
shoes and with the study subjects wearing light
clothes. Height was measured to the nearest 0.1 cm,
and weight was measured to the nearest 0.1 kg. BMI
was calculated as weight/height2 (kg/m2). Subjects
were classified into: (1) normal/overweight; (2) obese;
and (3) severely obese, based on a definition of obesity
for the population in Taiwan, with BMI cut-off values
of 27 and 30 kg/m2, respectively. Waist circumference
was measured to the nearest 0.1 cm at the level be-
tween the midpoint of the lowest rib and iliac crest
parallel to the floor in a standing position, while the
hip circumference was measured to the nearest 0.1 cm
at maximum extension of the buttocks. The waist-to-
hip ratio was calculated as an index of central obesity.
Percent body fat was measured by bioelectrical imped-
ance analysis (BIA) using the Tanita TBF-410 Body Fat
Analyzer (Tanita Corp., Tokyo, Japan). The instrument
has been previously validated against dual-energy 
X-ray absorptiometry [12]. Subjects were requested
not to eat or drink anything for at least 2 hours and to
refrain from strenuous exercise or consuming alcohol
for 12 hours before BIA measurement to avoid per-
turbation of hydration status. Blood pressure was
measured using a sphygmomanometer; two readings
were taken at 10-minute intervals after subjects had
been seated for at least 10 minutes. The two readings
were averaged.
Adipocytokines, insulin resistance and
metabolic profiles
Fasting glucose, total cholesterol, high-density lipopro-
tein (HDL) cholesterol, triglyceride, insulin, leptin,
and adiponectin were measured using blood samples
obtained after the participants had fasted overnight.
Cholesterol, HDL cholesterol, and triglyceride con-
centrations were analyzed by enzymatic colorimetric
methods and the fasting glucose level was measured
by the glucose oxidase method. At 2 hours after a 75-g
oral glucose tolerance test, blood was drawn and the
glucose level was measured by a glucose dehydroge-
nase method. The 2-hour glucose level was used as
an index of abnormal glucose metabolism. Using cri-
teria established by the World Health Organization
in 1999 [13], we classified our subjects into those with
normal glucose levels, impaired fasting glucose,
impaired glucose tolerance (IGT), or type 2 diabetes.
Subjects with type 2 diabetes were excluded from the
study. Plasma leptin, adiponectin and insulin levels
were measured using a radioimmunoassay from Linco
Research, Inc. (St Charles, MO, USA); intra- and in-
terassay coefficients of variation were 3.9% and 4.6%
for leptin, 6.2% and 6.9% for adiponectin, and 2.2%
and 3.8% for insulin, respectively. Insulin resistance
was estimated from the homeostasis model assessment
of insulin resistance (HOMA-IR) originally described
by Matthews et al [14] as follows:
HOMA-IR = [fasting insulin concentration (μU/
mL) × fasting glucose concentration (mmol/L)]/22.5.
Statistical analysis
Descriptive data are expressed as means and standard
deviations or frequencies and percentages. Pearson
correlation coefficients were used to determine the
associations between leptin, adiponectin and contin-
uous variables. Linear trends of leptin and adipo-
nectin levels and metabolic parameters was tested
across the three obesity subgroups using the Mantel-
Haenszel test with adjustment for age, exercise and
smoking status. Multiple regression analysis was used
to examine the association between parameters of in-
sulin resistance (HOMA-IR, fasting insulin levels or
2-hour glucose levels) and adipocytokines (leptin and
adiponectin) after adjusting for age, smoking status
and exercise. Multiple logistic regression analysis was
used to explore the association between IGT (2-hour
glucose level > 140 mg/dL) and adipocytokines after
controlling for potential confounding factors such as
age, BMI, fasting glucose level, fasting insulin level,
triglyceride, HDL cholesterol and blood pressure. All
statistical operations were performed using Stata SE
software version 9.0 (StataCorp LP, College Station,
TX, USA). A p value of less than 0.05 was considered
significant.
RESULTS
Descriptive data are shown in Table 1. The subjects
with BMI ≥ 30 kg/m2 were, on average, slightly
younger than those in the other two groups (Table 1).
Regular exercisers were more prevalent in the rela-
tively lean group (BMI < 27 kg/m2). The prevalence of
current smokers was less than 10% in all three groups.
Mean values for fasting glucose, 2-hour glucose, tri-
glycerides, insulin, HOMA-IR, leptin, and systolic and
diastolic blood pressure increased with increasing
BMI, after adjusting for age, exercise and smoking
status. In contrast, levels of HDL cholesterol and adipo-
nectin increased with decreasing BMI. Table 2 shows
that plasma leptin was positively correlated with
measures of obesity, fasting insulin and HOMA-IR,
but was not correlated with fasting glucose, 2-hour
glucose, triglycerides, HDL cholesterol or blood pres-
sure. Adiponectin was negatively correlated with
measures of obesity, fasting insulin, HOMA-IR, 2-hour
glucose levels and triglycerides, and positively corre-
lated with HDL cholesterol. Leptin and adiponectin
levels were inversely and significantly correlated.
The associations between leptin, adiponectin,
insulin resistance and hyperinsulinemia are shown in
Table 3. The multiple linear regression analyses re-
vealed that serum leptin levels were positively and
significantly associated with HOMA-IR (R2 = 31.6%)
and insulin level (R2 = 39.2%), but not 2-hour glucose
after controlling for the effects of adiponectin, age,
smoking status, exercise and BMI. Serum adiponectin
levels were negatively and significantly associated
with HOMA-IR, insulin level and 2-hour glucose,
after controlling for the effects of leptin, age, smoking
status, exercise and BMI.
We then dichotomized the subjects for the pres-
ence of IGT and found that adiponectin level, but not
leptin level, was significantly associated with IGT after 
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controlling for covariates including age, BMI, exer-
cise, smoking status, fasting glucose, HDL cholesterol,
triglycerides, fasting insulin, systolic blood pressure
and diastolic blood pressure (Table 4). Every 1 ng/dL
increase in adiponectin level was associated with a
0.22-fold decreased risk of having IGT. When we cat-
egorized subjects according to adiponectin levels into
tertiles, we found that subjects in the highest adipo-
nectin tertile (>9.1μg/dL) had significantly decreased
risk of having IGT (odds ratio, 0.03; 95% confidence
interval, 0.004–0.30; p = 0.002) compared with those in
the lowest tertile, after controlling for other covariates
including age, BMI, exercise, smoking status, fasting
glucose, HDL cholesterol, triglycerides, fasting insulin,
systolic blood pressure and diastolic blood pressure
(Table 4). In contrast, we found no significant effect of
leptin level, by tertiles, on the risk of IGT.
DISCUSSION
The aim of our study was to examine the associations
between leptin, adiponectin and insulin resistance
after controlling for obesity and other covariates, be-
cause leptin, adiponectin and insulin resistance are
all highly correlated with obesity. We found that higher
BMI levels were associated with higher concentra-
tions of leptin, fasting insulin, HOMA and lower con-
centrations of adiponectin. The physiologic function
of leptin is to provide a signal to the brain to decrease
appetite, increase fuel consumption and control stores
of body fat in rodents and humans [6,15]. However,
instead of leptin deficiency, the leptin concentration
was positively associated with adiposity in our
study. Moreover, other studies have revealed that the
elevated circulating plasma leptin does not suppress
appetite or prevent fat deposition in obese humans
[16], which suggests that hyperleptinemia rather than
leptin deficiency is a common feature of human obe-
sity, because the concentrations of leptin in plasma
may reflect the degree of body adiposity in most
human beings. In contrast to leptin, adiponectin was
decreased in the obese subjects in our study and in
other studies [10,17], even though adiponectin is
mainly synthesized in adipose tissue. Taken together,
obese subjects tend to have high levels of leptin, low
levels of adiponectin and hyperinsulinemia.
Obesity, particularly visceral obesity, is an impor-
tant risk factor for insulin resistance. The significant
positive association between BMI and insulin resis-
tance (HOMA-IR and fasting insulin level) was also
demonstrated in our study. Whether the association
Adipocytokines and insulin resistance
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Table 1. Participant characteristics and metabolic measures according to degree of obesity
BMI < 27 27 ≤ BMI < 30 BMI ≥ 30 
(n = 70) (n = 58) (n = 62)
Age (yr) 42.9 ± 12.0 41.6 ± 9.4 36.5 ± 12.0
Current smoker (%) 5 (7.1) 2 (3.5) 5 (8.1)
Exercise (%) 32 (45.7) 28 (48.3) 25 (40.3)
BMI (kg/m2) 24.4 ± 1.8 28.4 ± 0.8 34.6 ± 4.2
Waist-to-hip ratio 0.82 ± 0.06 0.85 ± 0.06 0.85 ± 0.05
Waist circumference 82.0 ± 6.4 90.1 ± 6.4 99.4 ± 9.7
% body fat 34.0 ± 4.5 40.0 ± 4.3 47.6 ± 7.5
p for trend*
Fasting glucose (mg/dL) 91.7 ± 8.3 94.6 ± 10.7 93.8 ± 12.0 0.04
2-hr glucose (mg/dL) 105.3 ± 27.3 110.1 ± 29.4 116.6 ± 31.1 0.004
TG (mg/dL) 105.1 ± 55.5 134.0 ± 64.3 138.0 ± 62.3 0.001
HDL cholesterol (mg/dL) 59.5 ± 16.2 53.4 ± 13.4 50.2 ± 9.0 < 0.0001
Fasting insulin (μIU/mL) 6.2 ± 5.0 9.2 ± 6.6 15.7 ± 9.0 < 0.0001
HOMA-IR (μUmol−1L−3) 1.5 ± 1.4 2.2 ± 1.7 3.6 ± 2.1 < 0.0001
Leptin (μg/dL) 15.5 ± 8.0 19.6 ± 6.6 30.6 ± 12.6 < 0.0001
Adiponectin (μg/dL) 10.5 ± 5.3 7.5 ± 3.8 7.0 ± 3.3 < 0.0001
SBP (mmHg) 123.1 ± 13.1 131.1 ± 15.4 131.8 ± 14.0 < 0.0001
DBP (mmHg) 79.8 ± 9.5 84.5 ± 9.8 85.0 ± 9.4 0.0001
*Trend analysis was adjusted for age, exercise and smoking status. BMI = body mass index; TG = triglycerides; HDL = high-density
lipoprotein; HOMA-IR = homeostasis model assessment of insulin resistance; SBP = systolic blood pressure; DBP = diastolic blood
pressure.
between obesity and insulin resistance is causal or
due to an underlying association with confounding
variables remains to be clarified. Therefore, our analy-
ses were adjusted for measures of obesity and poten-
tial confounding factors to examine the relationship
between leptin, adiponectin and insulin resistance.
The results revealed that high leptin levels and low
adiponectin levels were independently associated with
hyperinsulinemia and insulin resistance, suggesting
that high leptin levels and low adiponectin levels are
associated with hyperinsulinemia and insulin resis-
tance independently of obesity, and may play a role in
the development of insulin resistance. Boden et al [18]
observed that prolonged infusion of insulin depen-
dently increases serum leptin concentration during
euglycemic-hyperinsulinemic clamps in non-obese
young men. Some studies also showed that insulin can
stimulate leptin secretion due to increased triglyceride
storage in fat cells [19,20], while leptin may directly
suppress insulin secretion from pancreatic islets iso-
lated from ob/ob mice and humans [21,22]. However,
insulin secretion did not affect leptin synthesis in
hyperleptinemic insulin-resistant individuals inde-
pendently of the level of obesity [7]. Taken together,
these findings suggest that there is a feedback path-
way between leptin and insulin secretion, but the 
development of “insulin insensitivity” or “leptin
insensitivity” could adversely affect the association
between leptin and insulin, and stimulate the pro-
gression to hyperinsulinemia and impaired glucose
metabolism.
The relationship between adiponectin and insulin
resistance/hyperinsulinemia in our study can be
explained by some experimental studies. Expression
of the adiponectin receptor was detected in rat and
human β-cells [23] and the expression of adiponectin
can be stimulated by insulin [17], which suggests that
adiponectin may modulate β-cell function. The admin-
istration of adiponectin to normal, obese and diabetic
rodents decreased gluconeogenesis in the liver and
increased fatty acid oxidation in muscle [24] and thus
regulates insulin sensitivity and energy homeostasis.
However, the effect of adiponectin on insulin secre-
tion is controversial. Staiger et al [25] demonstrated
that adiponectin does not affect insulin secretory
function of healthy human islets in vitro. Winzell et al
[26] reported a dual effect of adiponectin to modify
insulin secretion in insulin-resistant mice because
adiponectin inhibited insulin secretion at low glucose
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(2.8 mM) but augmented insulin secretion at high
glucose (16.7 mM) concentration. In contrast, adipo-
nectin did not have an acute effect on insulin secre-
tion in islets from normal mice. Therefore, we believe
that adiponectin modulates insulin secretion but 
involves a complicated mechanism. Recent studies
have found that the adiponectin level is decreased in
patients with type 2 diabetes or coronary heart dis-
ease [28], and is associated with anti-inflammation
[27,28]. One randomized interventional trial of weight
reduction revealed that body weight reductions were
associated with increased adiponectin levels and 
decreased levels of inflammatory factors such as 
C-reactive protein, tumor necrosis factor (TNF)-α, and
interleukin (IL)-6 [29], indicating that adiponectin
might protect against inflammation and atherosclerosis.
However, it has also been reported that inflammatory
mediators, such as TNF-α and IL-6, which are in-
creased in obese and insulin resistant individuals, can
suppress the transcription of adiponectin in adipo-
cyte cell lines [30,31], which explains, at least in part,
the decreased level of adiponectin in obese subjects.
Leptin, adiponectin and IGT
We found that the level of adiponectin, but not leptin,
was associated with 2-hour glucose level after con-
trolling for BMI, age, cigarette smoking and exercise
status. We then classified the study subjects into those
with or without IGT, and found that high adiponectin
levels were independently associated with decreased
risk of developing IGT (odds ratio, 0.78) after control-
ling for possible confounding variables including
BMI, age, fasting glucose level, HDL cholesterol, tri-
glycerides, fasting insulin concentration, systolic and 
Adipocytokines and insulin resistance
Kaohsiung J Med Sci March 2009 • Vol 25 • No 3 121
Table 3. Multiple regression analyses of adipocytokines and insulin resistance*
HOMA-IR Insulin 2-hr glucose
B SE p B SE p B SE p
BMI 0.10 0.04 0.004 0.44 0.14 0.002 0.31 0.60 NS
Leptin 0.03 0.02 0.036 0.16 0.06 0.009 0.16 0.26 NS
Adiponectin −0.09 0.03 0.001 −0.36 0.11 0.001 −1.87 0.46 < 0.0001
Model R2 31.6 39.2 15.3
*Each model was adjusted for age, cigarette smoking and exercise. HOMA-IR = homeostasis model assessment of insulin resistance;
BMI = body mass index; SE = standard error.
Table 4. Multiple regression analysis for leptin, adiponectin and the presence of impaired glucose tolerance
No. of subjects with IGT Model 1* Model 2†
Yes/No OR (95% CI) OR (95% CI)
Leptin
Continuous 1.01 (0.95–1.108)
Tertiles (μg/dL)
< 15.7 10/53 Reference
15.7–23.7 10/52 1.04 (0.32–3.40)
> 23.7 11/54 2.27 (0.48–10.65)
Adiponectin
Continuous 0.78 (0.67–0.92)
Tertiles (μg/dL)
< 5.9 17/46 Reference
5.9–9.1 13/50 0.67 (0.27–1.69)
> 9.1 1/63 0.03 (0.004–0.30)
*Adjusted for age, body mass index, exercise, smoking status, fasting glucose, high-density lipoprotein cholesterol, triglycerides, 
fasting insulin, systolic and diastolic blood pressure, and leptin and adiponectin were analyzed as continuous variables in the model;
†adjusted for age, body mass index, exercise, smoking status, fasting glucose, high-density lipoprotein cholesterol, triglycerides, 
fasting insulin, systolic and diastolic blood pressure, and leptin and adiponectin were analyzed as categorical variables in the model.
IGT = impaired glucose tolerance; OR = odds ratio; CI = confidence interval.
diastolic blood pressure, cigarette smoking and exer-
cise. Meanwhile, subjects in the highest adiponectin
tertile had the lowest risk of having IGT. IGT has been
used as a marker for insulin resistance [32], denoting a 
pre-diabetic state in which subjects are at increased risk
of progressing to diabetes [33], premature mortality
and cardiovascular disease [34]. These findings sug-
gest that low levels of adiponectin may be involved
in the pathogenesis of abnormal glucose metabolism.
A prospective cohort study by Snijder et al [35] has
reported that low levels of adiponectin are indepen-
dently associated with a higher risk of IGT and type 2
diabetes in elderly Caucasian women. Another study
by Tso et al [36] revealed that polymorphisms of
ADIPOQ, the gene encoding adiponectin, was associ-
ated with glycemic status in southern Chinese people,
suggesting a biomolecular mechanism for adiponectin
and abnormal glucose metabolism. However, we did
not find an association between leptin and 2-hour
glucose level and IGT after controlling for BMI and
other possible confounding factors, suggesting that
leptin is less important in the development of IGT.
Wannamethee et al [37] reported that the association
between leptin and type 2 diabetes disappeared in
older men after adjusting for insulin resistance in a
prospective cohort study. Similarly, Kanaya et al [38]
reported that the association between leptin and the
incidence of type 2 diabetes disappeared after adjust-
ing for metabolic syndrome-related factors. However,
Panarotto et al [39] reported that leptin is indepen-
dently associated with IGT and type 2 diabetes in
Caucasian females, although that study did not deter-
mine adiponectin. Therefore, the associations between
leptin and impaired glucose metabolism may be
mediated by insulin resistance and other factors.
The limitation of our study is that the cross-
sectional design prohibits us from inferring a causal
relationship. Second, most of our study subjects were
obese because they were recruited from obesity clinics.
Therefore, the study subjects may be more insulin-
resistant and thus skew the data; however, after log-
transforming our data (which was carried out before
data analysis and which we have not shown in this
paper) and adjusting for potential confounding factors,
the results remained valid and the significance should
not be ignored. Third, we did not collect nutritional
information from the study subjects; therefore, possible
associations between nutritional effects, adipocytokines
and insulin resistance are not clear in our study.
Obesity is associated with the development of the
metabolic syndrome, a cluster of metabolic abnor-
malities, including hypertension, abnormal glucose
metabolism, dyslipidemia, and hyperuricemia. Insulin
resistance and compensatory hyperinsulinemia may
be a potential link between obesity [40]. Therefore,
early detection of insulin resistance is important for
early intervention and prevention of obesity-related
comorbidities.
In conclusion, we found associations between leptin
and adiponectin and obesity and related metabolic
disorders, although the associations were in opposite
directions. Leptin and adiponectin were both associated
with insulin resistance and hyperinsulinemia inde-
pendently of obesity, suggesting that leptin and adipo-
nectin may be involved in the pathophysiologic link
between obesity and insulin resistance. However, low
levels of adiponectin, but not leptin, were associated
with 2-hour glucose levels and IGT, suggesting that
adiponectin is a potential determinant for the progres-
sion of insulin resistance to type 2 diabetes, and low
levels of adiponectin might predict the increased risk
of developing impaired glucose metabolism, type 2 dia-
betes, premature mortality and cardiovascular disease.
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非糖尿病女性之脂肪細胞激素與胰島素
阻抗之相關性研究
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肥胖是胰島素阻抗及第二型糖尿病的危險因子。最近發現，由脂肪細胞所分泌的一些蛋白
質 (瘦體素、酯聯素 ) 與胰島素阻抗性有關。本篇研究目的在於探討非糖尿病女性其脂肪
細胞酵素包括瘦體素、酯聯素與胰島素抗阻及葡萄糖不耐症之間的相關性。個案選自在 
2003 年 2 月至 2004 年 2 月間小港醫院準備參加減重門診的婦女，排除已知有糖尿病的患
者以及目前正在使用降血壓、降血脂及降血糖的藥物後，共有 190 位個案。以問卷收集個
案的基本資料，生活習慣，過去疾病史及藥物史。所有個案在隔夜空腹後抽血分析血糖、
總膽固醇、高密度膽固醇、三酸甘油酯、胰島素及瘦體素、酯聯素。所有個案在給予口服 
75 克葡萄糖水試驗後 2 小時，抽血測量血糖值以判斷個案是否有葡萄糖不耐症。計算 
HOMA-IR 作為胰島素抗阻程度的指標，並且測量血壓、腰圍及 BMI。統計分析以皮爾斯
相關分析 BMI、胰島素、瘦體素及酯聯素間的相關性；以複迴歸分析控制相關因子後分析
瘦體素、酯聯素與胰島素阻抗的相關性。多變數分析的結果顯示，在控制了包括 BMI 在
內的相關變數後，瘦體素及酯聯素兩者分別與 HOMA-IR 或空腹胰島素濃度有顯著的統計
相關，其中瘦體素與 HOMA-IR 及空腹胰島素濃度為正相關，而酯聯素與 HOMA-IR 及
空腹胰島素濃度為負相關。而控制了包括 BMI 在內的可能干擾因子後，adiponectin 與
葡萄糖不耐症仍有顯著的統計相關，瘦體素則無統計上的顯著差異。在控制了肥胖的因素
後，瘦體素和酯聯素分別與胰島素抗阻性及空腹胰島素濃度之間仍有顯著統計相關，推論
分泌自脂肪細胞的瘦體素及酯聯素可能與肥胖者發生胰島素阻抗的機轉有關。而在控制了
肥胖等相關因子後，酯聯素與葡萄糖不耐症仍有統計上顯著差異，推論較低的血清酯聯素
濃度可能與發生血糖代謝異常或糖尿病有相關，而瘦體素則較無關。
關鍵詞：脂肪細胞激素，酯聯素，胰島素抗阻性，瘦體素，肥胖
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